Mapping Genes for Type 2 (Non-Insulin Dependent) Diabetes Mellitus
![]() |
The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details. |
ClinicalTrials.gov Identifier: NCT00339885 |
Recruitment Status :
Completed
First Posted : June 21, 2006
Last Update Posted : May 27, 2020
|
- Study Details
- Tabular View
- No Results Posted
- Disclaimer
- How to Read a Study Record
The aim of the project is to positionally clone susceptibility genes for NIDDM. Patients will be ascertained in Finland from previous health surveys and hospital discharge records. Approximately 400 affected sib pairs will be collected. Families will be chosen who have, at most, one parent with NIDDM no history of IDDM. A clinical examination will be undertaken on family members and blood drawn for DNA isolation. Covariates such as body weight, blood pressure, lipid levels and urinary albumin will also be measured. The unaffected spouse and children of a subset of probands will be invited to undergo a frequently-sampled intravenous glucose tolerance test (FSIGT) to measure parameters of pancreatic function and peripheral insulin resistance (IR). A number of unrelated elderly non-diabetic subjects will also be identified to conduct a population-based association analysis.
The FSIGT analysis will be performed in Los Angeles. The DNA will be shipped to Bethesda where a total genomic scan will be performed using semi-automated fluorescence-based genotyping technology. Data from Bethesda, Los Angeles and Finland will be sent to Ann Arbor where parametric and non-parametric methods will be used to analyse both discrete traits such as NIDDM and intermediate traits like IR....
Condition or disease |
---|
Genetic Variation Diabetes |
The Finland-United States investigation of NIDDM (FUSION) study is a long-term effort to
identify susceptibility genes for Type 2 diabetes (T2D) and associated quantitative traits. This
involves the phenotyping and DNA analysis of thousands of individuals living in Finland, utilizing a study design that was originally based on affected sib pairs. The majority of these samples have already been subjected to a genome scan using microsatellite markers and the original FUSION samples. Additionally, thousands of other northern European cases and controls have been subjected to genome-wide association (GWA) analysis and/or fine mapping as part of the FUSION study. More recently, the opportunity provided by the lowered sequencing costs have allowed targeted and/or whole genome sequencing of many of these individuals.
Study Type : | Observational |
Actual Enrollment : | 32379 participants |
Observational Model: | Case-Control |
Time Perspective: | Other |
Official Title: | Mapping Genes for Type 2 (Non-Insulin Dependent) Diabetes Mellitus |
Actual Study Start Date : | June 1, 1996 |
Actual Primary Completion Date : | May 22, 2020 |
Actual Study Completion Date : | May 22, 2020 |

Group/Cohort |
---|
AADM
Family and Population based individuals
|
Action-LADA
Population based individuals
|
D2D 2004
Population based individuals
|
DIAGEN (Dresden Biobank)
Population based individuals
|
FINRISK 1987
Population based individuals
|
FINRISK 2002
Population based individuals; Test DNA
|
Fusion 1
Affected-sib pair (ASP) families and elderly controls
|
Fusion 2
275 Replication ASP Families; Trios
|
Fusion 3
Siblings of FUSION1 families; Spouses, Offspring of 291 FUSION 1 families; Spouses, Offspring of Elderly Controls; Other F1 relatives
|
Fusion 4/5
Spouses, Offspring of FUSION 1 and 2 Families
|
FUSION Finnish Groups
Family and Population based (including METSIM and DR's EXTRA): Tissue samples
|
Health-2000
Population based individuals
|
HUNT 2
Population based individuals
|
METSIM
Population based individuals
|
Savitaipale
Population based individuals
|
UEF - Laakso
Monogenic disease individuals and family members
|
- T2D status, quantitative traits measurements [ Time Frame: ongoing ]Association testing
Biospecimen Retention: Samples With DNA

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.
Ages Eligible for Study: | 1 Month to 65 Years (Child, Adult, Older Adult) |
Sexes Eligible for Study: | All |
Accepts Healthy Volunteers: | Yes |
Sampling Method: | Non-Probability Sample |
- No eligibility criteria listed.

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT00339885
Finland | |
Natl Inst for Health & Welfare (THL) | |
Helsinki, Finland | |
Research Ethics Committee of Hospital District of Northern Savo | |
Kuopio, Finland | |
Norway | |
University of Tromso | |
Tromso, Norway | |
Norwegian U of Science & Technology | |
Trondheim, Norway |
Principal Investigator: | Lori Bonnycastle, Ph.D. | National Human Genome Research Institute (NHGRI) |
Responsible Party: | National Human Genome Research Institute (NHGRI) |
ClinicalTrials.gov Identifier: | NCT00339885 |
Other Study ID Numbers: |
999995030 OH95-HG-N030 |
First Posted: | June 21, 2006 Key Record Dates |
Last Update Posted: | May 27, 2020 |
Last Verified: | May 2020 |
Studies a U.S. FDA-regulated Drug Product: | No |
Studies a U.S. FDA-regulated Device Product: | No |
Monogenic Diabetes Type 2 Diabetes Mellitus QTL |
Diabetes Mellitus Glucose Metabolism Disorders Metabolic Diseases Endocrine System Diseases |